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Background: Nanosized dry powder inhalers provide higher stability for poorly water-soluble 
drugs as compared with liquid formulations. However, the respirable particles must have a 
  diameter of 1–5 µm in order to deposit in the lungs. Controlled agglomeration of the   nanoparticles 
increases their geometric particle size so they can deposit easily in the lungs. In the lungs, they 
fall apart to reform nanoparticles, thus enhancing the dissolution rate of the drugs. Theophylline 
is a bronchodilator with poor solubility in water.
Methods: Nanosized theophylline colloids were formed using an amphiphilic surfactant and 
destabilized using dilute sodium chloride solutions to form the agglomerates.
Results: The theophylline nanoparticles thus obtained had an average particle size of 290 nm 
and a zeta potential of −39.5 mV , whereas the agglomerates were 2.47 µm in size with a zeta 
potential of −28.9 mV . The release profile was found to follow first-order kinetics (r2 . 0.96). 
The aerodynamic characteristics of the agglomerated nanoparticles were determined using a 
cascade impactor. The behavior of the agglomerate was significantly better than unprocessed raw 
theophylline powder. In addition, the nanoparticles and agglomerates resulted in a significant 
improvement in the dissolution of theophylline.
Conclusion: The results obtained lend support to the hypothesis that controlled agglomera-
tion strategies provide an efficient approach for the delivery of poorly water-soluble drugs into 
the lungs.
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Introduction
Drug delivery to the lungs using dry powder inhalers has attracted scientific and biomedi-
cal attention in recent years.1–4 It has many advantages over other sites of administration 
because it has a fast onset of action, high bioavailability, avoidance of the first-pass effect, 
local action for pulmonary diseases, and convenience to patients when administered.4,5 
Theophylline is a bronchodilator and is efficient in the treatment of asthma and stable 
chronic obstructive pulmonary disease.6,7 However, there is a t  endency to reduce its use 
due to its complicated pharmacokinetic characteristics.8–15 It has a very narrow thera-
peutic window so that the range between the therapeutic dose and the toxic dose is quite 
narrow.11,14,16,17 Theophylline is a poorly water-soluble drug.18,19 Increasing the solubility 
of theophylline may reduce the border between the effective concentration and the toxic 
concentration.20 Theophylline is used in c  onjunction with small doses of beta agonists in 
the treatment of asthma;21 however, this combination may cause side effects, including 
hypokalemia.15,22,23 Particular care is m  andatory when introducing or withdrawing drugs 
that i  nteract with t  heophylline. A plasma theophylline   concentration of 10–20 mg/L is International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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required to achieve a t  herapeutic effect. Adverse effects can 
occur within a range of 10–20 mg/L.14 The severity of side 
effects increases at concentrations above 20 mg/L.16 Many 
side effects can occur due to a theophylline overdose, such as 
tachycardia, palpitations, central nervous system stimulation, 
arrhythmias and convulsions; it can also induce life-threatening 
seizures in humans, especially in infants.10,24,25 Therefore, cur-
rent oral doses of theophylline need to be controlled or reduced 
to minimize the danger of toxicity.
The administration of bronchodilators in dry powder 
aerosol form is one of the proposed strategies that can be 
adopted to reduce doses and, consequently, to reduce the side 
effects. Because inhaled powders work locally in the lung as 
a common site of action, lower doses are needed to achieve 
the same therapeutic effect as the oral doses.
The aerodynamic diameter has been used for several 
decades to measure the intrinsic tendency of aerosol 
particles to deposit in the lungs, due to their shape, density, 
and g  eometric size. In several studies, the most favorable 
particle size of aerosol particles was determined for several 
different drugs when given to patients. The optimal size of 
the particles for deposition in the lungs was found to be in 
the 1–5 µm range.26,27 For porous particles, which have a low 
density, their aerodynamic diameter can be smaller than their 
corresponding geometric diameter,28 therefore they can be 
used to improve drug deposition in peripheral regions.
There has been huge success in processing dry powder 
inhalers using a range of drug substances, including nifedipine, 
ciprofloxacin, tacrolimus, and budesonide.29–33 To the best of 
our knowledge, this is the only study demonstrating the use of 
agglomerated nanoparticles of theophylline as a dry powder 
for inhalers. Therefore, the aim of this study was to formulate 
self-assembled, theophylline nanoparticle agglomerates as 
a dry powder for inhalers. Nanoparticle were employed and 
manipulated to form self-assembled spherical rose-shaped 
agglomerates via destabilization of negatively charged nano-
sized theophylline powders. Stearic acid, as an amphiphilic 
moiety, was used as a stabilizer for the nanosuspension and the 
charges provided by stearic acid facilitated the agglomeration 
of the nanoparticles with addition of electrolytes. The nano-
particle agglomerates produced were found to have excellent 
inhalation properties and improved physicochemical properties 
compared with the unprocessed drug.
Materials and methods
Materials
Theophylline, stearic acid, and sodium chloride were 
p  rovided by El Gomhoria CO (Arab Republic of Egypt). 
Ethanol  (95%  v/v)  and  dimethylformamide  were 
p  urchased from Fisher Scientific (Egypt) and used without 
m  anipulation. Phosphate-buffered saline was purchased 
from Sigma C  hemicals (Egypt). Eighteen ohm water was 
obtained from a Millipore unit present at Helwan University 
(Cairo, Egypt).
Processing of nanotheophylline
Nanoparticles were prepared according to the procedure 
of Plumely et al, with some modifications.29 Theophylline 
40 mg and stearic acid either 5% or 10% w/w were dissolved 
in dimethylformamide 12 mL and ethanol 1 mL and then 
allowed to mix overnight. This solution was added to water 
60 mL via a microsyringe under probe sonication (Bandolin 
Electronic, model GM2200, GmbH) at low amplitude and 
20 second cycles for a total time of 120 seconds. The r  esulting 
nanoparticles were either stored at 4°C or were frozen at 
−20°C, then lyophilized using a freeze dryer (EF03, Edwards 
High Vacuum Ltd, UK).
Agglomerations of the nanoparticles
Nanoparticle suspensions were agglomerated by ionic 
i  nteraction of a diluted solution of strong electrolytes. 
D  ifferent increments of diluted NaCl salt solutions that 
ranged from 0.5 mL to 1.0 mL (1 × 10−3 M) were added 
to the nanosuspension solutions (73 mL). The nanosus-
pensions were then mixed vigorously at 2000 rpm for 
10 minutes. The samples were left at room temperature 
for 24 hours and then lyophilized (EF03, Edwards High 
Vacuum Ltd). The samples were stored in glass vessels in 
the refrigerator until further use. The effect of the concen-
trated electrolytes on agglomeration of the nanoparticles 
was investigated using NaCl salt solutions ranging from 
0.5–1.0 mL (0.1 M).
Physicochemical characterization of the 
nanoparticles and the agglomerates
Solid state characterization
The tapped and untapped densities (fluff) were evaluated using 
a small graduated tube with a defined volume size into which 
known weights of the powders were added. Dividing the mass 
of the powder by the volume is known as bulk d  ensity. Tapping 
this tube up and down against a protected bench 100 times 
corresponded with the tapped volume. Dividing the weight of 
the new volume gave the tapped density. The Hausner ratio is 
calculated by dividing the tapped density/bulk density. Carr’s 
index is calculated using Equation 1:
 C i = (tapped d-bulk d)/tapped   d × 100%  (1)International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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The angle of repose was calculated by forming a pile that 
was carefully built up by allowing the powders to fall through 
a funnel until the tip of the funnel was 2 cm apart. The angle 
of repose was calculated using the ratio between the height 
and the radius of the pile formed.
Particle size and zeta potential analysis
The mean particle size diameter and polydispersity index 
were measured in solution directly after synthesis using 
photon correlation spectroscopy (Mastersizer, Malvern, UK). 
Theophylline nanosuspensions and agglomerates (2 mL) 
were added to the quartz cell of the photon c  orrelation 
spectroscope. Measurements were taken at 90° opposite 
the incident light source. A fixed volume of the samples 
were used to measure the zeta potential of the nanoparticles. 
The pH was adjusted to different pH values. Zeta potential 
values were measured by a Zetasizer 2000 (Malvern) using 
KC1 (1 mM) as the running buffer.
calculation of the recovery
The agglomerates were evaluated both as a suspension and 
as a dry powder. After controlled agglomeration was recog-
nized, a small volume (2 mL) of each sample was examined 
using photon correlation spectroscopy (Malvern Mastersizer, 
UK). After lyophilization, the recovery was calculated using 
Equation (2):
  Recovery = Wp/WI × 100  (2)
where the weight of the powder produced (WP) is the weight 
of the solid weight after lyophilization, and the weight of 
added powder (WI) includes the weights of both the added 
theophylline and stearic acid.
Scanning electron microscopy
Samples of the theophylline powder, nanosuspension, and 
agglomerates as dry powders were mounted on copper 
stubs and coated with gold using the coating sputter (S150A 
Edwards, UK). The sample was examined under a JXA-840A 
electron probe microanalyzer (Jeol, Japan).
Differential scanning calorimetry
Theophylline powder, stearic acid, theophylline nanopar-
ticles, and theophylline agglomerates (4 mg) were sealed 
in the flat-bottomed aluminum pan of the differential scan-
ning calorimeter (Shimadzu DSC-50, Japan). A standard 
empty pan was inserted along with each pan to account 
for the heating of pure aluminum. The sample and the 
blank were continuously purged with nitrogen gas at a 
flow rate of 25 mL/min. Data collection was carried out 
at a temperature range of 20–300°C, and the heating rate 
was 10°C/min. The melting and transition point measure-
ments were performed using the software provided with 
the device.
Dissolution study
Dissolution was carried out using dry samples of nanoparticles, 
agglomerated nanoparticles, and theophylline powder (4 mg ) 
each, suspended in phosphate-buffered saline (1 mL, pH 7.4) 
and released into the dissolution medium through a dialysis 
bag with a molecular weight cut off of 12,000 Da. The sink 
conditions were achieved using 10 times the volume of satu-
ration solubility. The samples of nanoparticles, nanoparticle 
agglomerates, and theophylline powder were withdrawn at 
specified intervals over eight hours. The samples were mea-
sured spectrophotometrically at λ274 (Jasco V530, Japan).
Aerodynamic characterization
Total emitted dose
Amounts of pure powder, nanoparticles and agglomerate, 
equivalent to theophylline 80 mg, were separately placed 
into capsules suitable for the dry powder inhaler in order to 
test their aerodynamic characteristics (Aerolizer, Novartis 
Pharma, Egypt). The dose emitted from the Aerolizer was 
measured using a dry powder inhaler sampling apparatus with 
a critical flow controller (model TPK, Copley Scientific Ltd, 
UK). The final filter was a 47 mm A/E fiberglass filter disc 
(Pall   Corporation, Washington, NY). The inhalation flow 
through the mouthpiece of the Aerolizer was set at 60 L/min 
with a flow duration of four seconds to allow an inhaled 
volume of 4 L of air to be drawn through the inhaler.34–36 The 
dose emitted from the Aerolizer was measured by collecting 
one individual dose each time. The emitted dose test was 
repeated 10 times for each formula (n = 10).
Following dose emission into the apparatus, the sampling 
unit was washed and the filter was completely submerged in 
10% methanol and then sonicated for three minutes. The amount 
of drug was determined by high performance   liquid chroma-
tography37 using a monolithic column RP-18e 100 × 4.6 mm 
through which a mobile phase of m  ethanol-10 mM KH2PO4 
(pH 4) at a ratio of 12.5:87.5% v/v, was pumped at 1 mL/min. 
The ultraviolet detector (RF-551, Shimadzu, Japan) was set at 
a wavelength of 274 nm. The limit of detection was 0.014 µg/
mL and the lower limit of quantification was 0.041 µg/mL.
Aerodynamic particle size characterization
All parts of the Andersen MKII Cascade Impactor (i  ncluding 
the preseparator) were washed in methanol and allowed to International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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dry. The impactor was assembled with the modification plates 
for a flow rate of 60 L/min, hence stages 0 and 7 were replaced 
by −0 and −1 on the top of the impactor. The c  ollection plates 
were then sprayed with silicone fluid (R  eleasil B silicone 
spray, Dow Corning Limited, G  lamorgan, UK) and allowed 
to dry for at least one hour prior to analysis. The cascade 
impactor was assembled with 10 mL of 10% methanol placed 
in the preseparator and the final filter was a GF 50 (Copley 
Scientific Ltd).
The flow rate through the mouthpiece of the Aerolizer 
was set at 60 L/min through the impactor with a flow duration 
of four seconds (corresponding to 4 L through the inhaler). 
The flow was measured using an electronic digital flow 
meter (MKS Instruments, San Jose, CA) and a critical flow 
controller model TPK (Copley Scientific Ltd). Parafilm M 
laboratory film (Pechiney Plastic Packaging, Neenah, WI) 
was used to seal the apparatus.
The pump (set for the required flow) was switched on for 
the previously mentioned inhalation time to allow a volume of 
4 L of air, as recommended in the p  harmacopeial methods,34–36 
to be drawn through the inhaler during each determination. 
Only one dose was discharged into the i  mpactor for each 
determination. Five separate d  eterminations were made 
(n = 5) for each flow. Each stage of the cascade impactor 
was rinsed with a specified volume of methanol 10%. The 
washing procedure was the same as the procedure described 
for the total dose emission. The amounts deposited on 
each stage were determined by high-performance liquid 
chromatography.
Data analysis
The total dose emission was determined as the total amount 
of drug ex-mouthpiece. This was reported with respect to the 
nominal emitted dose. Using the impactor with a flow rate 
of 60 L/min, the effective cutoff diameter of each stage was 
fixed to 60 L/min flow.38,39 The fine particle dose was the 
amount of particles that corresponded to a size less than 5 µm. 
The fine particle fraction was the fine particle dose expressed 
as a percentage of the total amount deposited into the throat 
and stages of the cascade impactor (the dose that exited the 
mouthpiece). The mass median aerodynamic diameter was 
obtained from a plot of the logarithm of the percentage less 
than a stated size on a probability scale against the logarithm 
of the effective cutoff diameter of the stage,34–36 and this was 
done using Copley Inhaler Testing Data Analysis Software. 
The mass median aerodynamic diameter was the diameter 
corresponding to 50% undersize. The geometric standard 
deviation was the square root for the size corresponding to 
84.13% less than the stated size divided by the square root 
of the size for 15.87%.34–36 The aerodynamic results were 
compared using a paired t-test.
Results and discussion
The possibility of producing controlled agglomerates 
from a nanosuspension of poorly water-soluble drugs has 
been reported previously.29,40–43 However, many different 
techniques can be used to achieve this goal, such as using 
the nanoparticles,44 using the micronized form of poorly 
water-soluble drugs45,46 and even using four-fluid spray 
driers to prepare microparticles containing water-insoluble 
drugs.47–49 In this study, the theophylline agglomerate was 
prepared at a respirable particle size (1–5 µm) using the 
solvent antisolvent technique.29,45–50 First, the drug was 
dissolved with stearic acid in an organic solvent and then 
precipitated as nanoparticles by dropping this solution 
into an antisolvent. For a  gglomeration, the addition of 
  monovalent cations is a well known procedure resulting 
in the   agglomeration of phospholipids, solid lipid nano-
particles, and nanosuspensions.42,51,52 It was reported that 
different types of monovalent cations can be chosen in order 
to control the degree of agglomeration.53
The order of the capability of monovalent cations to 
induce the initial phase of the agglomeration of large phos-
pholipid vesicles was reported to be: Li+ . Na+ . K+ . Tris 
ions. Lithium is a toxic cation. Therefore, Na+ was used in 
this study to induce agglomeration.54
Stearic acid was chosen as the stabilizer because it pos-
sesses many advantages, including the fact that it works 
as an amphiphilic surfactant, is cheap, and has no cationic 
roots. For example, Mg stearate has Mg+2 as a cationic root, 
so it can interfere with the agglomeration process.55,56 Stearic 
acid exists in a solid state at room temperature, which is 
thought to help in the formation of a thin layer surrounding 
the drug nanodispersion.57 The amphiphilic nature of stearic 
acid makes it perform as a boundary between theophylline 
nanoparticles and the hydrophilic medium in the lungs.29
All of the nanosuspension formulations demonstrated a 
macroscopic homogenous appearance, which was pale cloudy 
white in color when examined by eye before l  yophilization. 
After lyophilization, they appeared as a flowing white   powder. 
The agglomerates produced were white fluffy powders com-
pletely different in their macroscopic characteristics from 
either the nanoparticles or the parent theophylline powder.
The amount of stearic acid added significantly affected 
the size of the nanoparticles produced. The particles with the 
smallest sizes were those produced with the highest ratio of International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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stearic acid (Table 1). The recovery was also improved by 
increasing the concentration of stearic acid used, which may 
have happened due to the repulsion occurring between the 
nanoparticle surfaces and the walls of the glass vessels upon 
transfer. The ratio between theophylline and stearic acid was 
presumed to remain the same after lyophilization in each case. 
Particle size analysis showed the presence of nanoparticles 
with low polydispersity indices (Table 1). The size 
d  istribution was in concurrence with other   nanosuspension 
systems described in the literature.29 The photon correla-
tion spectroscopy results were in agreement with the electron 
micrograph results. Scanning electron microscopy showed 
the formation of elliptically shaped nanoparticles that 
started to arrange themselves in rosy clusters once placed 
on a copper grid for the photographs (Figures 1A and 1B).   
This p  henomenon means that these nanoparticles can be 
destabilized in the presence of diluted concentrations of 
any cation. The agglomeration occurred in a dendritic shape 
(Figures 1C and 1D) which provided a porous structure with 
a much lower density than that of the pure drug. The shape 
of the agglomerates indicated the formation of the agglom-
erates in a sequential manner, starting from the core and 
finishing at the periphery. In literature it was reported that 
Table 1 The recovery, particle size, and polydispersity indices of 
theophylline nanoparticles and theophylline agglomerates
Particles Stearic acid  
(% w/w)
Recovery  
(%)
Particle size  
(nm)
PI
Nanoparticles 5 47 ± 07 470 ± 20 0.65 ± 0.14
10 70 ± 18 290 ± 22 0.21 ± 0.02
Agglomerates 5 66 ± 19 880 ± 180 0.55 ± 0.11
10 90 ± 03 2470 ± 120 0.67 ± 0.16
Abbreviation: PI, polydispersity index.
AB
D
F
C
E
10 µm x4000 8 µm x6000
5 µm x10000 10 µm x3000
10 µm x5000 10 µm x4000
Figure 1 Nanoparticles (A), close up of theophylline nanoparticles (B), theophylline controlled agglomerates (C), close up of theophylline controlled agglomerates (D), 
aggregation of theophylline nanoparticles upon using high concentration of Nacl (E), and theophylline powder without processing (F). Note the circles that showing the 
mechanism of self-assembly of nanorods on a copper grid. The arrows show fluffy spherical nanorods of the controlled agglomerates.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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the particles agglomerate spontaneously and it was thought 
that they grouped together without order during the agglom-
eration steps.29 Controlled agglomeration was achieved 
through the addition of a very diluted concentration of NaCl 
(0.5 mL, 10−3 M), as shown in Figures 1C and 1D, whereas 
aggregation was achieved by the addition of a 0.5 to 1 mL 
(0.1 M) concentration of NaCl, as shown in Figures 1E 
and 1F. The mean diameter of the agglomerate prepared 
using the diluted NaCl solution was of an average respirable 
size (1–5 µm), with a median particle size of 2.47 µm when 
stearic acid (10% w/w) was used. Less defined agglomerates 
were formed when a concentration of stearic acid lower than 
10% w/w was used (Table 1).
The surface characteristics of the nanoparticles were 
subjected to a thorough study at different NaCl concentra-
tions. Table 2 shows the differences in zeta potential values 
between nanoparticles and agglomerates at different pH 
ranges upon the addition of diluted NaCl solution (0.5 mL, 
10−3 M). At physiological pH, the agglomerated samples 
acquired a negative charge but to a lesser extent than that 
of the nanoparticles. The presence of these negative charges 
on the surface of the agglomerates kept the agglomerates in 
a definite shape (spheroidal agglomerates) when kept under 
dry conditions (Figures 1C and 1D) or when dissolved in 
water, as given by the photon correlation spectroscopy 
data (Table 1). The negative value of the zeta potential of 
the nanosuspensions reached −39.3 mV in the presence of 
10% stearic acid, whereas it decreased to −28.9 mV upon 
agglomeration. These values provided colloidal stability 
for both the nanoparticles and the agglomerates. Both 
of these values are far from the aggregation threshold 
defined by   Riddick. It was reported that a zeta potential 
value of nanoparticles of more than −30 mV indicates 
electrostatic repulsion among particles and is enough for 
good stability.58 A zeta potential range of −20 to −11 mV 
represents the threshold of aggregation as defined by Rid-
dick.58 Therefore, complete neutralization of the stearic 
acid using NaCl (0.5–1.0 mL, 0.1 M) was found to produce 
big agglomerates that formed nuclei for bigger aggregates 
over time (Figure 1E). At low pH levels, the nanoparticles 
and the agglomerates carried fewer negative charges than 
they carried at physiological pH. This may have been due 
to the lower degree of ionization of stearic acid at lower pH 
levels. This theory supports our assumption of stearic acid 
being the only provider of negative charges at the surface 
of the nanosuspension.
The percentage of the powders recovered differed mark-
edly between the nanoparticles and agglomerates (Table 1). 
This phenomenon can be elucidated in light of the flowability 
characteristics, because nanoparticles with poor flowability 
usually show a low recovery because of difficulties and losses 
when transferring them from the vessels.29 The flowability 
parameters for the sample containing stearic acid (10% w/w) 
are summarized in Table 3. The nanoparticles showed poorer 
flowability than the agglomerated particles, as predicted from 
both Carr’s index and the Hausner ratio. This poor flowability 
of the nanoparticles may equate to the tendency of the nanopar-
ticles to adhere to each other by increasing the particle-particle 
forces.59 The angle of repose shows that the nanoparticles 
had the poorest flow among all of the studied series, which is 
congruent with the other flow characteristics.
The theophylline agglomerate showed poor flowability 
as well, but to a lesser extent than that of the nanoparticles. 
This may be because the agglomerates had a mean particle 
size in the micro range, so they showed a lower tendency 
to reduce their surface area by forming bigger aggregates. 
The increase in the size of aerosol particles results in a lower 
surface area of particle-particle contact in a dry powder 
and a lower tendency for further aggregation, as reported 
by Edwards et al.28,60 This prevention of further aggrega-
tion means that less energy is necessary to aerosolize the 
agglomerates and hence results in an easier flow to the 
lungs. The densities of the theophylline powder, nano-
Table 2 The differences in zeta potential between nanoparticles 
and agglomerates at different ph ranges upon addition of diluted 
Nacl (0.5 mL, 10−3M) solution (n = 3)
pH value Zeta potential (mV)
Nanoparticles Agglomerates
3 −7.7 ± 0.5 −11.1 ± 1.2
5.5 −37.9 ± 2 −24.9 ± 2.1
7.4 −39.5 ± 0.7 −28.9 ± 0.7
Table 3 Flowability parameters of theophylline powder, theophylline nanoparticles, and nanorose agglomerates
Sample Bulk density 
(gm/cm3)
Tapped density 
(gm/cm3)
Carr’s 
index
Hausner 
ratio
Angle of 
repose (°C)
Powder 0.80 ± 0.3 1.40 ± 0.2 33 ± 2 1.5 65 ± 2
Nanoparticles 0.20 ± 0.02 0.29 ± 0.01 31 ± 6 1.45 80 ± 1
Agglomerate 0.04 ± 0.01 0.05 ± 0.03 25 ± 2 1.25 70 ± 2International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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particles, and the agglomerates are in agreement with the 
powder structure seen in the electromicrographs in Figure 1, 
which show the formation of less dense nanoagglomerates 
of theophylline, which differ dramatically from the dense 
theophylline powder.
Differential scanning calorimetry thermographs were 
used to investigate the presence of chemical interactions 
between theophylline and stearic acid, in addition to moni-
toring changes in the crystalline state of the theophylline 
powder, nanoparticles, and agglomerates (Figure 2 and 
Table 4). Both theophylline and stearic acid exhibited 
sharp endothermic peaks when they underwent a melting 
phenomenon upon heating (Figure 2). The results showed a 
lack of interaction between the drug and stearic acid, which 
suggested the formation of a physical mixture in the case 
of the nanosuspension. It was also found that the enthalpy 
of the nanoparticles was lower than that of the pure drug, 
which may be attributed to the presence of a small amount 
of stearic acid surrounding the progesterone without invad-
ing it. However, there was no clear evidence to support this 
theory. The results showed an absence of a significant shift 
in the endothermic peak of theophylline in all of the samples 
(the peak shifted from 274°C in the theophylline powder to 
be 273°C in the case of the theophylline nanoparticles and 
to be 273.39°C in the case of the agglomerates), which is an 
indication of the lack of significant changes in the crystal-
line state of theophylline in all samples, and hence it is an 
i  ndication of the presence of stearic acid on the surface but not 
within the theophylline molecules. The nanoparticles and the 
agglomerates showed lower peak areas on a per mass basis 
in contrast with the raw drug. It can be seen that the area of 
the peaks was reduced for the nanoparticles and, to a lesser 
extent, the agglomerates, which might be due to the higher 
surface area of both the nanoparticles and agglomerates in 
comparison with the theophylline. The results of the differ-
ential scanning calorimetry thermographs are summarized 
in Table 4 and Figure 2.
The in vitro dissolution profile of the nanoparticles, 
agglomerates, and theophylline powder (Figure 3) showed 
rapid release of the nanoparticles and the agglomerates in 
comparison with the theophylline powder. About 80%–90% 
of the nanoparticles were released throughout the duration 
of the experiment (eight hours). This rapid drug release was 
correlated with the particle size and increasing surface area of 
the nanoparticles. Therefore, small nanoparticles underwent 
a more rapid dissolution than both the agglomerate and the 
Theophylline Stearic acid Agg NP
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Figure 2 Differential scanning calorimetry thermograms for stearic acid, theophylline, theophylline nanoparticles, and theophylline agglomerates.
Table 4 Differential scanning calorimetry peak integrations for 
theophylline  powder,  stearic  acid  powder,  theophylline  nano­
particles, and theophylline agglomerates in the lyophilized form
Sample Peak location (°C) Enthalpy (J/g)
Theophylline 274.0 188
Stearic 60.0 387
Nanosuspension
  Theophylline peak 272.9 53.08
  Stearic peak 55.6 2.83
Theophylline agglomerate
  Theophylline peak 273.39 118
  Stearic peak 70.01 843.43International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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raw theophylline powder. About 69% of the agglomerate 
dissolved at the time of the experiment, and its dissolution 
profile overlaps with that of the nanoparticles at certain 
points. The difference was found to be significant at P , 0.05 
and the release kinetics were found to obey first-order kinetics 
with r2 . 0.96. This may indicate the presence of more than 
one type of release kinetics controlling the release, which 
may have occurred due to the adsorption of fine molecules 
on the outer interphase of the nanosuspension. These small 
molecules might have dissolved readily and therefore inter-
fered with the order of the release kinetics. This experiment 
indicates that the efficiency of both nanoparticles and the 
agglomerate in enhancing the release of the drug was higher 
than that of the raw theophylline powder alone. Therefore, 
both the agglomerate and nanosuspension might be dissolved 
rapidly in vivo.
The results of the aerodynamic characterization are 
shown in Table 5. The nanoparticles and the agglomerates 
resulted in significantly smaller mass median aerodynamic 
diameter (P , 0.05) and higher fine particle dose (P , 0.01), 
fine   particle fraction (P , 0.01), and TED (P , 0.01) than 
the pure powder. There were no significant differences 
between the nanoparticles and the agglomerates. However, 
the agglomerates had a higher emitted dose and a higher 
fine particle dose and a lower mass median aerodynamic 
diameter than the nanoparticles. This might be due to the 
small number of determinations made for each system 
(n = 5). This number was recommended by the compendial 
methods.34–36
These findings are consistent with those reported previ-
ously in the literature.29 The aerodynamic characterization 
showed no significant differences between the agglomerate 
and the nanoparticles in all aspects. However, they both 
resulted in better aerodynamic characteristics than the pure 
powder. Therefore, the use of theophylline in the form of 
agglomerate or nanoparticle aerosols may result in better 
lung d  eposition than the use of the pure powder. However, 
a significant d  ifference between the agglomerates and the 
nanoparticles might be recognized upon increasing the 
number of determinations, which would suggest that a future 
clinical bioequivalence test would be needed to consolidate 
this finding.
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Figure 3 cumulative drug released against time for the theophylline powder, theophylline nanoparticles, and theophylline agglomerates (n = 3 ± standard deviation).
Table 5 The aerodynamic characteristics of theophylline, theophylline nanoparticles, and theophylline agglomerates
Particles Theophylline Nanoparticles Agglomerates
Total emitted dose (µg) 59.9 ± 8.5 70.6 ± 6.7 72.3 ± 7.5
Total emitted dose (% of nominal dose) 75.5 ± 11.4 88.3 ± 9.4 90.4 ± 10.3
Fine particle dose (µg) 33.3 ± 12.2 55.4 ± 7.8 57.4 ± 6.7
Fine particle fraction (% of emitted dose) 55.6 ± 6.4 81.9 ± 4.3 79.4 ± 4.6
Mass median aerodynamic diameter (µm)   4.4 ± 1.2   2.5 ± 1.1   2.3 ± 0.9
geometric standard deviation   2.2 ± 0.5   1.6 ± 0.4   1.4 ± 0.3International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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